REPLIMUNE GROUP INC (REPL) Stock Price, Quote, News and Overview
NASDAQ:REPL - Nasdaq - US76029N1063 - Common Stock - Currency: USD
REPL Quote, Performance and Key Statistics
7.01
-0.4 (-5.4%)
The current stock price of REPL is 7.01 USD. In the past month the price decreased by -9.08%. In the past year, price increased by 8.85%.
REPL Competitors/Peers
Symbol | Company Name | TA | FA | PE | Market Cap |
|---|---|---|---|---|---|
| ABBV | ABBVIE INC | 17.28 | 313.89B | ||
| AMGN | AMGEN INC | 12.63 | 141.01B | ||
| GILD | GILEAD SCIENCES INC | 12.71 | 122.48B | ||
| VRTX | VERTEX PHARMACEUTICALS INC | N/A | 108.27B | ||
| REGN | REGENERON PHARMACEUTICALS | 12.89 | 61.69B | ||
| ALNY | ALNYLAM PHARMACEUTICALS INC | N/A | 34.80B | ||
| ARGX | ARGENX SE - ADR | 90.68 | 32.50B | ||
| ONC | BEIGENE LTD-ADR | 5.46 | 23.71B | ||
| BNTX | BIONTECH SE-ADR | N/A | 22.14B | ||
| NTRA | NATERA INC | N/A | 20.57B | ||
| BIIB | BIOGEN INC | 7.61 | 17.64B | ||
| SMMT | SUMMIT THERAPEUTICS INC | N/A | 16.90B |
Related stock screener links
About REPL
Company Profile
Replimune Group, Inc. is a clinical-stage biotechnology company. The company is headquartered in Woburn, Massachusetts and currently employs 331 full-time employees. The company went IPO on 2018-07-20. The Company’s proprietary RPx platform is based on a potent HSV-1 backbone intended to maximize immunogenic cell death and the induction of a systemic anti-tumor immune response. RP1 (vusolimogene oderparepvec) is its lead product candidate and is based on a proprietary strain of herpes simplex virus engineered and genetically armed with a fusogenic protein (GALV-GP R-) and GM-CSF intended to maximize tumor killing potency, the immunogenicity of tumor cell death, and the activation of a systemic anti-tumor immune response. The company is also developing additional product candidates, RP2 and RP3, to enhance anti-tumor immune responses and are intended to address additional tumor types, including traditionally less immune responsive tumor types. RP2 additionally expresses an anti-CTLA-4 antibody-like molecule, as well as GALV-GP R- and GM-CSF.
Company Info
REPLIMUNE GROUP INC
500 Unicorn Park Dr
Woburn MASSACHUSETTS 01801 US
CEO: Philip Astley-Sparke
Employees: 331
Phone: 17812229600
REPLIMUNE GROUP INC / REPL FAQ
What is the stock price of REPLIMUNE GROUP INC today?
The current stock price of REPL is 7.01 USD. The price decreased by -5.4% in the last trading session.
What is the ticker symbol for REPLIMUNE GROUP INC stock?
The exchange symbol of REPLIMUNE GROUP INC is REPL and it is listed on the Nasdaq exchange.
On which exchange is REPL stock listed?
REPL stock is listed on the Nasdaq exchange.
What is the price forecast or stock price prediction for REPLIMUNE GROUP INC stock?
14 analysts have analysed REPL and the average price target is 22 USD. This implies a price increase of 213.88% is expected in the next year compared to the current price of 7.01. Check the REPLIMUNE GROUP INC stock analysts ratings, price target forecast and up-and down grades for more detailed information.
What is REPLIMUNE GROUP INC worth?
REPLIMUNE GROUP INC (REPL) has a market capitalization of 539.84M USD. This makes REPL a Small Cap stock.
How many employees does REPLIMUNE GROUP INC have?
REPLIMUNE GROUP INC (REPL) currently has 331 employees.
What are the support and resistance levels for REPLIMUNE GROUP INC (REPL) stock?
REPLIMUNE GROUP INC (REPL) has a resistance level at 7.87. Check the full technical report for a detailed analysis of REPL support and resistance levels.
Should I buy REPLIMUNE GROUP INC (REPL) stock?
There is no straightforward answer here. It depends on your investment strategy as different types of investors will look at different aspects. In any case it is important to make an informed decision and these pages can help you forming an opinion:
- The Technical Analysis (TA) tab contains a technical analysis of REPL, looking at technical quality and support and resistance levels
- The Fundamental Analysis (FA) tab contains a fundamental analysis of REPL, evaluating the profitability, health, valuation and growth aspects
- REPLIMUNE GROUP INC (REPL) Price Target Forecast and Analysts Ratings to understand what professional analysts say.
- REPLIMUNE GROUP INC (REPL) Sales and EPS estimates to see what analysts future expectations are.
- REPLIMUNE GROUP INC (REPL) Income, Balance Sheet and Cash Flow statements to dive into the historical financials.
- REPLIMUNE GROUP INC (REPL) Insider and Institutional Ownership to learn about the owners and their transactions.
- REPLIMUNE GROUP INC (REPL) Stock Chart to make your own analysis
- REPLIMUNE GROUP INC (REPL) Latest news and press-releases to stay up to date.
Does REPLIMUNE GROUP INC (REPL) stock pay dividends?
REPL does not pay a dividend.
When does REPLIMUNE GROUP INC (REPL) report earnings?
REPLIMUNE GROUP INC (REPL) will report earnings on 2025-08-06.
What is the Price/Earnings (PE) ratio of REPLIMUNE GROUP INC (REPL)?
REPLIMUNE GROUP INC (REPL) does not have a PE ratio as the earnings reported over the last twelve months were negative (-3.07).
What is the Short Interest ratio of REPLIMUNE GROUP INC (REPL) stock?
The outstanding short interest for REPLIMUNE GROUP INC (REPL) is 12.67% of its float. Check the ownership tab for more information on the REPL short interest.
REPL Technical Analysis
REPL Fundamental Analysis
ChartMill assigns a fundamental rating of 2 / 10 to REPL. The financial health of REPL is average, but there are quite some concerns on its profitability.
REPL Financial Highlights
Over the last trailing twelve months REPL reported a non-GAAP Earnings per Share(EPS) of -3.07. The EPS increased by 2.85% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -37.81% | ||
| ROE | -47.32% | ||
| Debt/Equity | 0.14 |
REPL Ownership and Analysts
ChartMill assigns a Buy % Consensus number of 86% to REPL. The Buy consensus is the average rating of analysts ratings from 14 analysts.